Close Menu

The Wall Street Journal runs an article profiling multimillionaire and melanoma patient Jay Tenenbaum and the company he founded, CollabRx, to get patients involved in helping develop therapeutics faster and for less money than the process currently takes. The projects that CollabRx takes on are called "virtual biotechs," according to the story, "because they aim to replicate many of the steps typically taken as part of a pharmaceutical or biotech company's search for a new drug."

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.